

PSYCHIATRY
BOARD REVIEW SERIES
THE KAUFMAN COURSES

SPONSORED BY MONTEFIORE MEDICAL CENTER CREDIT DESIGNATED BY ALBERT EINSTEIN COLLEGE OF MEDICINE

Accreditation Statement: Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CLINICAL NEUROLOGY FOR PSYCHIATRISTS

David Myland Kaufman, MD

This intensive three-day weekend course, offered for the 37th year, is designed for psychiatrists in practice and in residency as an update or board preparation. Focusing on essential topics, the course will use lectures, extensive syllabus, and the new edition of Clinical Neurology for Psychiatrists, David M. Kaufman (6th edition, Elsevier).

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 25 *AMA PRA Category 1 Credit(s).™* Physicians should only claim credit commensurate with the extent of their participation in the activity.

LOS ANGELES
The Westin Hotel at the Los Angeles Airport
5400 West Century Boulevard, Los Angeles, CA 90045
Friday, March 27 to Sunday, March 29, 2009
7:45 AM – 5:30 PM

NEW YORK
The Graduate Center
City University of New York (CUNY)
Friday, April 17 to Sunday, April 19, 2009
8:15 AM – 6:00 PM

PSYCHIATRY FOR PSYCHIATRISTS

Andrea J. Weiss, MD and David Myland Kaufman, MD

This two-day course will be a pre-test that will complement standard psychiatry review courses and complete the review in Clinical Neurology for Psychiatrists. In this course, an expert group of faculty who are experienced and well-informed about modern psychiatry and test-taking strategies will present essential information through a series of test-type questions utilizing audience response system keypads and using answers for discussions and explanations.

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 16 *AMA PRA Category 1 Credit(s).™* Physicians should only claim credit commensurate with the extent of their participation in the activity.

LOS ANGELES
The Westin Hotel at the Los Angeles Airport
5400 West Century Boulevard, Los Angeles, CA 90045
Monday, March 30 to Tuesday, March 31, 2009
7:45 AM – 5:30 PM

NEW YORK
The Graduate Center
City University of New York (CUNY)
Monday, April 20 to Tuesday, April 21, 2009
8:15 AM – 6:00 PM

MAINTENANCE OF CERTIFICATION: THE RECERT COURSE

Dan Smuckler, MD, Andrea J. Weiss, MD and David Myland Kaufman, MD

This intensive two-day course designed for psychiatrists will review the psychiatric information likely to appear on the recertification examination. It will cover current evidence-based treatments for psychiatric disorders, emphasizing clinical matters and advances in diagnosis and treatment. Presentation of the material will be in a mixed format, with both lecture and question and answer utilizing audience response system keypads.

AMA Statement: Albert Einstein College of Medicine designates this educational activity for a maximum of 14.5 *AMA PRA Category 1 Credit(s).™* Physicians should only claim credit commensurate with the extent of their participation in the activity.

NEW YORK
SUNY College of Optometry (New Location)
Joseph and Roberta Schwarz Theater
33 West 42nd Street (Between 5th and 6th Avenues)
New York, NY 10036
Friday, January 30 to Saturday, January 31, 2009
7:45 AM – 5:30 PM

FOR MORE INFORMATION

- **Web site** Course Information or To Register: www.cnfp.org
- **Write:** CCME, 3301 Bainbridge Avenue, Bronx, NY 10467
- **E-mail:** cme@montefiore.org
- **Call:** 718-920-6674 • **Fax:** 718-798-2336

FAST TRACK REGISTRATION FORM... OR YOU CAN REGISTER ON-LINE AT www.cnfp.org

I Will Attend/Check One:

	Los Angeles	*New York City*
Clinical Neurology for Psychiatrists	☐ March 27-29 (Fri-Sun)	☐ April 17-19 (Fri-Sun)
Psychiatry: Pre-Test	☐ March 30-31 (Mon-Tues)	☐ April 20-21 (Mon-Tues)
Maintenance of Certification	Not Available	☐ Jan. 30-31 (Fri-Sat)

Check One:

	Practicing Physicians	*Residents & Fellows*
Clinical Neurology (Course)	☐ $975.00	☐ $850.00
Psychiatry: Pre-Test (Course)	☐ $600.00	☐ $500.00
Both courses	☐ $1,300.00	☐ $1,100.00
Text book only	☐ $110.00	☐ $110.00
Maintenance of Certification	☐ $495.00	

Make checks payable to Montefiore Medical Center or charge my

Visa ☐ MC ☐ AMEX ☐

Exp: ____ / ____

Signature _____

Name _____ Degree _____

Address _____

†we cannot mail the textbook to P.O. Boxes

City _____ State _____ Zip _____

Phone (_____) _____

Affiliation _____

e mail _____

Cancellation Policy: On written request, the registration fee is refundable, less $95 administration fee, until three weeks prior to each course. No refunds will be made thereafter.

For Additional Course Information And Sample Test Questions, Please Visit Our Web Site: www.cnfp.org

IN THE TREATMENT OF SCHIZOPHRENIA

INVEGA®
PALIPERIDONE®
Extended-Release Tablets

INVEGA® (paliperidone) extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION FOR INVEGA®

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® (paliperidone) is not approved for the treatment of patients with dementia-related psychosis.

Cerebrovascular Adverse Events (CAEs): CAEs, including fatalities, have been reported in elderly patients with dementia-related psychosis taking atypical antipsychotics in clinical trials. INVEGA® is not approved for treating these patients.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including INVEGA®. Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

QT Prolongation: INVEGA® causes a modest increase in the corrected QT (QTc) interval. INVEGA® should be avoided in combination with other drugs that are known to prolong the QTc interval, in patients with congenital long QT syndrome or a history of cardiac arrhythmias. Certain circumstances may increase the risk of torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval.

Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose. Elderly patients appeared to be at increased risk for TD. Prescribing should be consistent with the need to minimize the risk of TD. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS). Patients starting treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

Hyperprolactinemia: As with other drugs that antagonize dopamine D_2 receptors, INVEGA® elevates prolactin levels and the elevation persists during chronic administration.

Potential for Gastrointestinal Obstruction: INVEGA® should ordinarily not be administered to patients with pre-existing severe gastrointestinal narrowing. Rare instances of obstructive

Janssen®
Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

INVEGA®—Powerful Efficacy With Safety and Tolerability

Plus additional features to consider

Metabolism and Excretion

- CYP450 isozymes play a limited role in the overall metabolism of INVEGA®
  - — Less than 10% of the dose is metabolized by each of the 4 identified metabolic pathways*
- Primarily excreted unchanged via the kidneys
  - — Dosing must be individualized according to the patient's renal function status. The maximum recommended dose of INVEGA® is 6 mg for patients with mild renal impairment and 3 mg for patients with moderate to severe renal impairment

*Dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.

Innovative Drug Delivery System

- Innovative OROS® extended-release technology for reduced peak/trough fluctuations†[1]



†Correlation to clinical effect has not been established.

OROS is a registered trademark of ALZA Corporation.

symptoms have been reported in patients with known strictures taking nondeformable formulations. INVEGA® should only be used in patients who are able to swallow the tablet whole.

Orthostatic Hypotension and Syncope: INVEGA® may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period. Monitoring should be considered in patients for whom this may be of concern. INVEGA® should be used with caution in patients with known cardiovascular disease, and conditions that would predispose patients to hypotension.

Potential for Cognitive and Motor Impairment: INVEGA® has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that INVEGA® does not affect them adversely.

Seizures: INVEGA® should be used cautiously in patients with a history of seizures.

Suicide: The possibility of suicide attempt is inherent in psychotic illnesses and close supervision of high-risk patients should accompany drug therapy.

Maintenance Treatment: Physicians who elect to use INVEGA® for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.

Drug Interactions: Co-administration of INVEGA® 6 mg once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state C_{max} and AUC of paliperidone. On initiation of discontinuation of carbamazepine, the dose of INVEGA® should be re-evaluated and adjusted if necessary. Given the primary CNS effects of INVEGA®, INVEGA® should be used with caution in combination with other centrally acting drugs and the use of alcohol should be avoided.

Extrapyramidal Symptoms (EPS): Total EPS-related adverse events in the higher 9-mg and 12-mg treatment groups were 25% and 26%, respectively, versus 11% for the placebo group.

Weight Gain: The proportion of subjects having a weight gain of ≥7% body weight were comparable to placebo (5%) for 3 mg (7%) and 6 mg (6%). A higher incidence was seen for 9 mg (9%) and 12 mg (9%).

Renal Impairment: Dosing must be individualized according to the patient's renal function status. The maximum recommended dose of INVEGA® is 6 mg for patients with mild renal impairment and 3 mg for patients with moderate to severe renal impairment (see Dosing for Special Populations).

Elderly: No dosage adjustment is recommended based on age alone. However, dose adjustment may be required because of age-related decreases in creatinine clearance (see Dosing for Special Populations).

Commonly Observed Adverse Reactions: The most commonly observed adverse reactions, occurring at an incidence of ≥5% and at least 2 times placebo, were akathisia and extrapyramidal disorder.

Use with Risperidone: Concomitant use of paliperidone with risperidone has not been studied. Since paliperidone is the major active metabolite of risperidone, consideration should be given to the additive paliperidone exposure if risperidone is co-administered.

01JN776R1

Reference: 1. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22(10):1879-1892.

Please see brief summary of full Prescribing Information for INVEGA® on adjacent page.

For information on free or discounted prescription medications, visit access2wellness.com or call 866 317 2775.

access 2 wellness™

INVEGA®

(paliperidone) Extended-Release Tablets

Brief Summary

BEFORE PRESCRIBING INVEGA®, PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA® (paliperidone) Extended-Release Tablets is not approved for the treatment of patients with dementia-related psychosis. *[see Warnings and Precautions]*

INVEGA® (paliperidone) Extended-Release Tablets are indicated for the acute and maintenance treatment of schizophrenia *[see Clinical Studies in full PI]*.

CONTRAINDICATIONS

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. INVEGA® (paliperidone) is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in INVEGA®.

WARNINGS AND PRECAUTIONS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA® (paliperidone) is not approved for the treatment of dementia-related psychosis *[see Boxed Warning]*.

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients With Dementia-Related Psychosis: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. INVEGA® was not marketed at the time these studies were performed. INVEGA® is not approved for the treatment of patients with dementia-related psychosis *[see Boxed Warning]*.

Neuroleptic Malignant Syndrome: A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including paliperidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

QT Prolongation: Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

The effects of paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.

In the QT study (n = 141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate-release was more than twice the exposure observed with the maximum recommended 12 mg dose of INVEGA® (C_{max} ss = 113 ng/mL and 45 ng/mL, respectively, when administered with a standard breakfast). In this same study, a 4 mg dose of the immediate-release oral formulation of paliperidone, for which C_{max} ss = 35 ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% CI: 3.6; 10.1) on day 2 at 1.5 hours post-dose. None of the subjects had a change exceeding 60 msec or a QTcLD exceeding 500 msec at any time during this study.

For the three fixed-dose efficacy studies, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the INVEGA® 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec). No subject receiving INVEGA® had a QTcLD exceeding 500 msec at any time in any of these three studies.

Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, INVEGA® should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA®, drug discontinuation should be considered. However, some patients may require treatment with INVEGA® despite the presence of the syndrome.

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA®. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because INVEGA® was not marketed at the time these studies were performed, it is not known if INVEGA® is associated with this increased risk.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose

control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Hyperprolactinemia: Like other drugs that antagonize dopamine D_2 receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats *[see Nonclinical Toxicology in full PI]*. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Potential for Gastrointestinal Obstruction: Because the INVEGA® tablet is non-deformable and does not appreciably change in shape in the gastrointestinal tract, INVEGA® should ordinarily not be administered to patients with pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic, for example: esophageal motility disorders, small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel's diverticulum). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of drugs in non-deformable controlled-release formulations. Because of the controlled-release design of the tablet, INVEGA® should only be used in patients who are able to swallow the tablet whole *[see Dosage and Administration]*.

A decrease in transit time, e.g., as seen with diarrhea, would be expected to decrease bioavailability and an increase in transit time, e.g., as seen with gastrointestinal neuropathy, diabetic gastroparesis, or other causes, would be expected to increase bioavailability. These changes in bioavailability are more likely when the changes in transit time occur in the upper GI tract.

Orthostatic Hypotension and Syncope: Paliperidone can induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. In pooled results of the three placebo-controlled, 6-week, fixed-dose trials, syncope was reported in 0.8% (7/850) of subjects treated with INVEGA® (3 mg, 6 mg, 9 mg, 12 mg) compared to 0.3% (1/355) of subjects treated with placebo. INVEGA® should be used with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.

Potential for Cognitive and Motor Impairment: Somnolence and sedation were reported in subjects treated with INVEGA® *[see Adverse Reactions]*. Antipsychotics, including INVEGA®, have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that paliperidone therapy does not adversely affect them.

Seizures: During premarketing clinical trials (the three placebo-controlled, 6-week, fixed-dose studies and a study conducted in elderly schizophrenic subjects), seizures occurred in 0.22% of subjects treated with INVEGA® (3 mg, 6 mg, 9 mg, 12 mg) and 0.25% of subjects treated with placebo. Like other antipsychotic drugs, INVEGA® should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. INVEGA® and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Suicide: The possibility of suicide attempt is inherent in psychotic illnesses, and close supervision of high-risk patients should accompany drug therapy. Prescriptions for INVEGA® should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Priapism: Drugs with alpha-adrenergic blocking effects have been reported to induce priapism. Although no cases of priapism have been reported in clinical trials with INVEGA®, paliperidone shares this pharmacologic activity and, therefore, may be associated with this risk. Severe priapism may require surgical intervention.

Thrombotic Thrombocytopenic Purpura (TTP): No cases of TTP were observed during clinical studies with paliperidone. Although cases of TTP have been reported in association with risperidone administration, the relationship to risperidone therapy is unknown.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing INVEGA® to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Antiemetic Effect: An antiemetic effect was observed in preclinical studies with paliperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye's syndrome, and brain tumor.

Use in Patients with Concomitant Illness: Clinical experience with INVEGA® in patients with certain concomitant illnesses is limited *[see Clinical Pharmacology in full PI]*.

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

INVEGA® has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical trials. Because of the risk of orthostatic hypotension with INVEGA®, caution should be observed in patients with known cardiovascular disease *[see Warnings and Precautions]*.

Monitoring: Laboratory Tests: No specific laboratory tests are recommended.

ADVERSE REACTIONS

The following are discussed in more detail in other sections of the labeling:

- Increased mortality in elderly patients with dementia-related psychosis *[see Boxed Warning]*
- Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis *[see Warnings and Precautions]*
- Neuroleptic malignant syndrome *[see Warnings and Precautions]*
- QT prolongation *[see Warnings and Precautions]*
- Tardive dyskinesia *[see Warnings and Precautions]*
- Hyperglycemia and diabetes mellitus *[see Warnings and Precautions]*
- Hyperprolactinemia *[see Warnings and Precautions]*
- Potential for Gastrointestinal Obstruction *[see Warnings and Precautions]*
- Orthostatic hypotension and syncope *[see Warnings and Precautions]*
- Potential for cognitive and motor impairment *[see Warnings and Precautions]*
- Seizures *[see Warnings and Precautions]*
- Dysphagia *[see Warnings and Precautions]*
- Suicide *[see Warnings and Precautions]*
- Priapism *[see Warnings and Precautions]*
- Thrombotic thrombocytopenic purpura (TTP) *[see Warnings and Precautions]*
- Disruption of body temperature regulation *[see Warnings and Precautions]*
- Antiemetic effect *[see Warnings and Precautions]*
- Increased sensitivity in patients with Parkinson's disease or those with dementia with Lewy bodies *[see Warnings and Precautions]*
- Diseases or conditions that could affect metabolism or hemodynamic responses *[see Warnings and Precautions]*

The most common adverse reactions in clinical trials (reported in 5% or more of subjects treated with INVEGA® and at least twice the placebo rate in any of the dose groups) were akathisia and extrapyramidal disorder.

The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in 2% of INVEGA®-treated subjects) were nervous system disorders *[see Adverse Reactions]*.

The safety of INVEGA® was evaluated in 1205 adult subjects with schizophrenia who participated in three placebo-controlled, 6-week, double-blind trials, of whom 850 subjects received INVEGA® at fixed doses ranging from 3 mg to 12 mg once daily. The information presented in this section was derived from pooled data from these three trials. Additional safety information from the placebo-controlled phase of the long-term maintenance study, in which subjects received INVEGA® at daily doses within the range of 3 mg to 15 mg (n=104), is also included.

Adverse events during exposure to study treatment were obtained by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of INVEGA® (adverse drug reactions) based on the comprehensive assessment of the available adverse event information. A causal association for INVEGA® often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials: *Table 1* enumerates the pooled incidences of adverse reactions reported in the three placebo-controlled, 6-week, fixed-dose studies, listing those that occurred in 2% or more of subjects treated with INVEGA® in any of the dose groups, and for which the incidence in INVEGA®-treated subjects in any of the dose groups was greater than the incidence in subjects treated with placebo.

Table 1. Adverse Reactions in Short-Term, Fixed-Dose, Placebo-Controlled Trials in Adult Subjects with Schizophrenia*: Body System or Organ Class (Dictionary-derived Term) **Percent of Patients Reporting Event Placebo (N=355)** first, **INVEGA® 3 mg once daily (N=127)** second, **6 mg once daily (N=235)** third, **9 mg once daily (N=246)** fourth, **12 mg once daily (N=242)** fifth, **Total percentage of subjects with adverse reactions** 37, 48, 47, 54, 60; **Cardiac disorders:** Atrioventricular block first degree 1, 2, 0, 2, 1; Bundle branch block 2, 3, 1, 3, <1; Sinus arrhythmia 0, 2, 1, 1, <1; Tachycardia 7, 14, 12, 12, 14; **Gastrointestinal disorders:** Abdominal pain upper 1, 1, 3, 2, 2; Dry mouth 1, 2, 3, 1, 3; Salivary hypersecretion <1, 0, <1, 1, 4; **General disorders:** Asthenia 1, 2, <1, 2, 2; Fatigue 1, 2, 1, 2, 2; **Nervous system disorders:** Akathisia 4, 4, 3, 8, 10; Dizziness 4, 6, 5, 4, 5; Dystonia 1, 1, 1, 5, 4; Extrapyramidal disorder 2, 5, 2, 7, 7; Headache 12, 11, 12, 14, 14; Hypertonia 1, 2, 1, 4, 3; Parkinsonism 0, 0, <1, 2, 1; Somnolence 7, 6, 9, 10, 11; Tremor 3, 3, 3, 4, 3; **Vascular disorders:** Orthostatic hypotension 1, 2, 1, 2, 4. * Table includes adverse reactions that were reported in 2% or more of subjects in any of the INVEGA® dose groups and which occurred at greater incidence than in the placebo group. Data are pooled from three studies; one study included once-daily INVEGA® doses of 3 mg and 9 mg, the second study included 6 mg, 9 mg, and 12 mg, and the third study included 6 mg and 12 mg *[see Clinical Studies in full PI]*. Adverse reactions for which the INVEGA® incidence was equal to or less than placebo are not listed in the table, but included the following: vomiting.

Less Commonly-Observed Adverse Reactions: The following list contains all serious and non-serious adverse reactions reported at any time by individuals taking INVEGA® during any phase of a trial within the premarketing database (n = 2720), except (1) those listed in *Table 1* above or elsewhere in labeling, (2) those for which a causal relationship to INVEGA® use was considered remote, and (3) those occurring in only one subject treated with INVEGA® and that were not acutely life-threatening. **Cardiac disorders:** bradycardia, palpitations **Gastrointestinal disorders:** abdominal pain, swollen tongue **General disorders:** edema **Immune system disorders:** anaphylactic reaction **Vascular disorders:** ischemia

Discontinuations Due to Adverse Reactions: The percentages of subjects who discontinued due to adverse reactions in the three placebo-controlled, 6-week, fixed-dose studies were 3% and 1% in INVEGA®- and placebo-treated subjects, respectively. The most common reasons for discontinuation were nervous system disorders (2% and 0% in INVEGA®- and placebo-treated subjects, respectively).

Dose-Related Adverse Reactions: Based on the pooled data from the three placebo-controlled, 6-week, fixed-dose studies, among the adverse reactions that occurred with a greater than 2% incidence in the subjects treated with INVEGA®, the incidences of the following adverse reactions increased with dose: somnolence, orthostatic hypotension, akathisia, dystonia, extrapyramidal disorder, hypertonia, Parkinsonism, and salivary hypersecretion. For most of these, the increased incidence was seen primarily at the 12 mg dose, and, in some cases, the 9 mg dose.

Demographic Differences: An examination of population subgroups in the three placebo-controlled, 6-week, fixed-dose studies did not reveal any evidence of differences in safety on the basis of gender or race alone; there was also no difference on the basis of age *[see Use in Specific Populations]*.

Extrapyramidal Symptoms (EPS): Pooled data from the three placebo-controlled, 6-week, fixed-dose studies provided information regarding treatment-emergent EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline) which evaluates akathisia, (3) use of anticholinergic medications to treat emergent EPS (*Table 2*), and (4) incidence of spontaneous reports of EPS (*Table 3*). For the Simpson-Angus Scale, spontaneous EPS reports and use of anticholinergic medications, there was a dose-related increase observed for the 9 mg and 12 mg doses. There was no difference observed between placebo and INVEGA® 3 mg and 6 mg doses for any of these EPS measures.

Table 2. Treatment-Emergent Extrapyramidal Symptoms (EPS) Assessed by Incidence of Ratings Scales and Use of Anticholinergic Medication: EPS Group Percentage of Patients Placebo (N=355) first, **INVEGA® 3 mg once daily (N=127)** second, **6 mg once daily (N=235)** third, **9 mg once daily (N=246)** fourth, **12 mg once daily (N=242)** fifth, Parkinsonism [a] 9, 11, 3, 15, 14; Akathisia [b] 6, 6, 4, 7, 9; Use of anticholinergic medications [c] 10, 10, 9, 22, 22. a: For Parkinsonism, percent of patients with Simpson-Angus global score > 0.3 (Global score defined as total sum of items score divided by the number of items) b: For Akathisia, percent of patients with Barnes Akathisia Rating Scale global score ≥ 2 c: Percent of patients who received anticholinergic medications to treat emergent EPS

Table 3. Treatment-Emergent Extrapyramidal Symptoms (EPS)-Related Adverse Events by MedDRA Preferred Term: EPS Group Percentage of Patients Placebo (N=355) first, **INVEGA® 3 mg once daily (N=127)** second, **6 mg once daily (N=235)** third, **9 mg once daily (N=246)** fourth, **12 mg once daily (N=242)** fifth, Overall percentage of patients with EPS-related AE 11, 13, 10, 25, 26; Dyskinesia 3, 5, 3, 8, 9; Dystonia 1, 1, 1, 5, 5; Hyperkinesia 4, 4, 3, 8, 10; Parkinsonism 2, 3, 3, 7, 6; Tremor 3, 3, 3, 4, 3; Dyskinesia group includes: Dyskinesia, extrapyramidal disorder, muscle twitching, tardive dyskinesia Dystonia group includes: Dystonia, muscle spasms, oculogyration, trismus Hyperkinesia group includes: Akathisia, hyperkinesia Parkinsonism group includes: Bradykinesia, cogwheel rigidity, drooling, hypertonia, hypokinesia, muscle rigidity, musculoskeletal stiffness, parkinsonism Tremor group includes: Tremor

Laboratory Test Abnormalities: In the pooled data from the three placebo-controlled, 6-week, fixed-dose studies, a between-group comparison revealed no medically important differences between INVEGA® and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA® and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglyceride, HDL, LDL, and total cholesterol measurements. However, INVEGA® was associated with increases in serum prolactin *[see Warnings and Precautions]*.

Weight Gain: In the pooled data from the three placebo-controlled, 6-week, fixed-dose studies, the proportions of subjects meeting a weight gain criterion of ≥ 7% of body weight were compared, revealing a similar incidence of weight gain for INVEGA® 3 mg and 6 mg (7% and 6%, respectively) compared with placebo (5%), and a higher incidence of weight gain for INVEGA® 9 mg and 12 mg (9% and 9%, respectively).

Other Findings Observed During Clinical Trials: The safety of INVEGA® was also evaluated in a long-term trial designed to assess the maintenance of effect with INVEGA® in adults with schizophrenia *[see Clinical Studies]*. In general, adverse reaction types, frequencies, and severities during the initial 14-week open-label phase of this study were comparable to those observed in the 6-week, placebo-controlled, fixed-dose studies. Adverse reactions reported during the long-term double-blind phase of this study were similar in type and severity to those observed in the initial 14-week open-label phase.

Adverse Reactions Reported With Risperidone: Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with risperidone can be found in the ADVERSE REACTIONS section of the risperidone package insert.

DRUG INTERACTIONS

Potential for INVEGA® to Affect Other Drugs: Given the primary CNS effects of paliperidone *[see Adverse Reactions]*, INVEGA® should be used with caution in combination with other centrally acting drugs and alcohol. Paliperidone may antagonize the effect of levodopa and other dopamine agonists.

Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA® is administered with other therapeutic agents that have this potential *[see Warnings and Precautions]*.

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. *In vitro* studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.

Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No *in vivo* data are available and the clinical relevance is unknown.

Potential for Other Drugs to Affect INVEGA®: Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. While *in vitro* studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, *in vivo* studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance. *In vitro* studies have shown that paliperidone is a P-gp substrate.

Co-administration of INVEGA® 6 mg once daily with carbamazepine 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration. On initiation of carbamazepine, the dose of INVEGA® should be re-evaluated and increased if necessary. Conversely, on discontinuation of carbamazepine, the dose of INVEGA® should be re-evaluated and decreased if necessary.

Paliperidone is metabolized to a limited extent by CYP2D6 *[see Clinical Pharmacology in full PI]*. In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA® was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.

USE IN SPECIFIC POPULATIONS

Pregnancy: Pregnancy Category C: There are no adequate and well controlled studies of INVEGA® in pregnant women. INVEGA® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Use of first generation antipsychotic drugs during the last trimester of pregnancy has been associated with extrapyramidal symptoms in the neonate. These symptoms are usually self-limited. It is not known whether paliperidone, when taken near the end of pregnancy, will lead to similar neonatal signs and symptoms.

In animal reproduction studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated during the period of organogenesis with up to 8 times the maximum recommended human dose of paliperidone (on a mg/m^2 basis).

In rat reproduction studies with risperidone, which is extensively converted to paliperidone in rats and humans, there were increases in pup deaths seen at oral doses which are less than the maximum recommended human dose of risperidone on a mg/m^2 basis (see risperidone package insert).

Labor and Delivery: The effect of INVEGA® on labor and delivery in humans is unknown.

Nursing Mothers: Paliperidone is 9-hydroxyrisperidone, the active metabolite of risperidone. In animal studies, risperidone and 9-hydroxyrisperidone were excreted in milk. Risperidone and 9-hydroxyrisperidone are also excreted in human breast milk. Caution should be exercised when INVEGA® is administered to a nursing woman. The known benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone.

Pediatric Use: Safety and effectiveness of INVEGA® in patients < 18 years of age have not been established.

Geriatric Use: The safety, tolerability, and efficacy of INVEGA® were evaluated in a 6-week placebo-controlled study of 114 elderly subjects with schizophrenia (65 years of age and older, of whom 21 were 75 years of age and older). In this study, subjects received flexible doses of INVEGA® (3 mg to 12 mg once daily). In addition, a small number of subjects 65 years of age and older were included in the 6-week placebo-controlled studies in which adult schizophrenic subjects received fixed doses of INVEGA® (3 mg to 15 mg once daily) *[see Clinical Studies in full PI]*.

Overall, of the total number of subjects in clinical studies of INVEGA® (n = 1796), including those who received INVEGA® or placebo, 125 (7.0%) were 65 years of age and older and 22 (1.2%) were 75 years of age and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with moderate to severe renal impairment *[see Clinical Pharmacology in full PI]*, who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function *[see Dosage and Administration in full PI]*.

Renal Impairment: Dosing must be individualized according to the patient's renal function status *[see Dosage and Administration in full PI]*.

Hepatic Impairment: No dosage adjustment is required in patients with mild to moderate hepatic impairment. INVEGA® has not been studied in patients with severe hepatic impairment.

PATIENT COUNSELING INFORMATION

Physicians are advised to discuss the following issues with patients for whom they prescribe INVEGA®.

Orthostatic Hypotension: Patients should be advised that there is risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose *[see Warnings and Precautions]*.

Interference with Cognitive and Motor Performance: As INVEGA® has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that INVEGA® therapy does not affect them adversely *[see Warnings and Precautions]*.

Pregnancy: Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with INVEGA® *[see Use in Specific Populations]*.

Nursing: Caution should be exercised when INVEGA® is administered to a nursing woman. The known benefits of breastfeeding should be weighed against the unknown risks of infant exposure to paliperidone. *[See Use in Specific Populations]*.

Concomitant Medication: Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions *[see Drug Interactions]*.

Alcohol: Patients should be advised to avoid alcohol while taking INVEGA® *[see Drug Interactions]*.

Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding overheating and dehydration *[see Warnings and Precautions]*.

Administration: Patients should be informed that INVEGA® should be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice something that looks like a tablet in their stool *[see Dosage and Administration in full PI]*.

Manufactured by: ALZA Corporation
Mountain View, CA 94043

OR

Janssen Cilag Manufacturing, LLC
Gurabo, Puerto Rico 00778

Janssen™
Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Manufactured for: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Titusville, NJ 08560

10105903B
Revised: September 2008

01JN821BS

REALIZE THE POSSIBILITIES

Gina, 37

Real Patient, Manager
Diagnosis: Bipolar Disorder
Last Episode: Mixed

- **Effectively treats acute manic and mixed episodes**
- **Well-established tolerability profile**
- **Target 120–160 mg/day on Day 2**
- **Initiate dosing at 80 mg/day with meals**

GEODON is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic symptoms.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with certain other QT-prolonging drugs. **GEODON has been associated with prolongation of the QT_c interval. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. Patients who are at risk for electrolyte disturbances should have baseline measurements performed before initiating GEODON. Patients on diuretics should be monitored.**

As with all antipsychotic medications, a rare and potentially fatal condition known as neuroleptic malignant syndrome (NMS) has been reported with GEODON. NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation, treatment, and monitoring are recommended.

Prescribing should be consistent with the need to minimize tardive dyskinesia (TD), a potentially irreversible dose- and duration-dependent syndrome. If signs and symptoms appear, discontinuation should be considered since TD may remit partially or completely.

Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia.

Precautions include the risk of rash, orthostatic hypotension, and seizures.

The most common adverse events associated with GEODON in bipolar mania were somnolence, extrapyramidal symptoms, dizziness, akathisia, and abnormal vision.

In short-term schizophrenia clinical trials, 10% of GEODON-treated patients experienced a weight gain of ≥7% of body weight vs 4% for placebo.

Individual results may vary.

Please see brief summary of prescribing information on adjacent page.

For more information, please visit www.pfizerpro.com/GEODON

GEODON®
(ziprasidone HCl) **Capsules**

BRIEF SUMMARY. See package insert for full prescribing information.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis—Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Geodon (ziprasidone) is not approved for the treatment of patients with Dementia-Related Psychosis (see WARNINGS).

INDICATIONS—GEODON Capsules is indicated for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder with or without psychotic features. GEODON® (ziprasidone mesylate) for Injection is indicated for acute agitation in schizophrenic patients.

CONTRAINDICATIONS — *QT Prolongation:* Because of GEODON's dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, GEODON is contraindicated in patients with a known history of QT prolongation (including congenital long QT syndrome), with recent acute myocardial infarction, or with uncompensated heart failure (see **WARNINGS**). Pharmacokinetic/pharmacodynamic studies between GEODON and other drugs that prolong the QT interval have not been performed. An additive effect of GEODON and other drugs that prolong the QT interval cannot be excluded. Therefore, GEODON should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, or tacrolimus. GEODON is also contraindicated with drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning (see **WARNINGS**). GEODON is contraindicated in individuals with a known hypersensitivity to the product. **WARNINGS — *Increased Mortality in Elderly Patients with Dementia-Related Psychosis:* Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON (ziprasidone) is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING). *QT Prolongation and Risk of Sudden Death:* GEODON use should be avoided in combination with other drugs that are known to prolong the QT_c interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the QT_c interval. Such drugs should not be prescribed with GEODON. A study directly comparing the QT/QT_c-prolonging effect of GEODON with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. The mean increase in QT_c from baseline for GEODON ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine. In this study, the effect of GEODON on QT_c length was not augmented by the presence of a metabolic inhibitor (ketoconazole 200 mg bid). In placebo-controlled trials, GEODON increased the QT_c interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials the electrocardiograms of 2/2988 (0.06%) GEODON patients and 1/440 (0.23%) placebo patients revealed QT_c intervals exceeding the potentially clinically relevant threshold of 500 msec. In the GEODON patients, neither case suggested a role of GEODON. Some drugs that prolong the QT/QT_c interval have been associated with the occurrence of torsade de pointes and with sudden unexplained death. The relationship of QT prolongation to torsade de pointes is clearest for larger increases (20 msec and greater) but it is possible that smaller QT/QT_c prolongations may also increase risk, or increase it in susceptible individuals, such as those with hypokalemia, hypomagnesemia, or genetic predisposition. Although torsade de pointes has not been observed in association with the use of GEODON at recommended doses in premarketing studies, experience is too limited to rule out an increased risk. A study evaluating the QT/QT_c prolonging effect of intramuscular GEODON, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of GEODON (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular GEODON is 50% higher than the recommended therapeutic dose. The mean change in QT_c from baseline was calculated for each drug using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QT_c from baseline for GEODON was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QT_c from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patient had a QT_c interval exceeding 500 msec. As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking GEODON at recommended doses. The premarketing experience for GEODON did not reveal an excess of mortality for GEODON compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, GEODON's larger prolongation of QT_c length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for GEODON than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products. Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QT_c interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QT_c interval; and (4) presence of congenital prolongation of the QT interval. GEODON should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias (see CONTRAINDICATIONS, and see *Drug Interactions* under PRECAUTIONS). It is recommended that patients being considered for GEODON treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during GEODON treatment. Persistently prolonged QT_c intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, GEODON should be avoided in patients with histories of significant cardiovascular illness, eg, QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. GEODON should be discontinued in patients who are found to have persistent QT_c measurements >500 msec. *Neuroleptic Malignant Syndrome (NMS):*** A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported. ***Tardive Dyskinesia (TD):*** A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of TD appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop TD. If signs and symptoms of TD appear in a patient on GEODON, drug discontinuation should be considered. ***Hyperglycemia and Diabetes Mellitus:*** Hyperglycemia-related adverse events, sometimes serious, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with GEODON, and it is not known if GEODON is associated with these events. Patients treated with an atypical antipsychotic should be monitored for symptoms of hyperglycemia. **PRECAUTIONS — *General:*** Rash: In premarketing trials, about 5% of GEODON patients developed rash and/or urticaria, with discontinuation of treatment in about one-sixth of these cases. The occurrence of rash was dose related, although the finding might also be explained by longer exposure in higher-dose patients. Several patients with rash had signs and symptoms of associated systemic illness, e.g., elevated WBCs. Most patients improved promptly upon treatment with antihistamines or steroids and/or upon discontinuation of GEODON, and all patients were reported to recover completely. Upon appearance of rash for which an alternative etiology cannot be identified, GEODON should be discontinued. Orthostatic Hypotension: GEODON may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose-titration period, probably reflecting its α_1-adrenergic antagonist properties. Syncope was reported in 0.6% of GEODON patients. GEODON should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). Seizures: In clinical trials, seizures occurred in 0.4% of GEODON patients. There were confounding factors that may have contributed to seizures in many of these cases. As with other antipsychotic drugs, GEODON should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia, and GEODON and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. **(See also Boxed WARNING, WARNINGS: Increased Mortality in Elderly Patients with Dementia-Related Psychosis)**. Hyperprolactinemia: As with other drugs that antagonize dopamine D_2 receptors, GEODON elevates prolactin levels in humans. Tissue culture experiments indicate that approximately one third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. Potential for Cognitive and Motor Impairment: Somnolence was a commonly reported adverse event in GEODON patients. In the 4- and 6-week placebo-controlled trials, somnolence was reported in 14% of GEODON patients vs 7% of placebo patients. Somnolence led to discontinuation in 0.3% of patients in short-term clinical trials. Since GEODON has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that GEODON therapy does not affect them adversely. Priapism: One case of priapism was reported in the premarketing database. Body Temperature Regulation: Although not reported with GEODON in premarketing trials, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Suicide: The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. GEODON prescriptions should be written for the smallest quantity of capsules consistent with good patient management to reduce overdose risk. Use in Patients with Concomitant Illness: Clinical experience with GEODON in patients with certain concomitant systemic illnesses is limited. GEODON has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of QT_c prolongation and orthostatic hypotension with GEODON, caution should be observed in cardiac patients (see ***QT Prolongation and Risk of Sudden Death*** in **WARNINGS** and Orthostatic Hypotension in **PRECAUTIONS**). ***Information for Patients:*** To ensure safe and effective use of GEODON, the information and instructions in the *Patient Information Section* should be discussed with patients. ***Laboratory Tests:*** Patients being considered for GEODON treatment who are at risk of significant electrolyte disturbances should have baseline serum potassium and magnesium measurements. Low serum potassium and magnesium should be repleted before treatment. Patients who are started on diuretics during GEODON therapy need periodic monitoring of serum potassium and magnesium. Discontinue GEODON in patients who are found to have persistent QT_c measurements >500 msec (see **WARNINGS**). ***Drug Interactions:*** (1) GEODON should not be used with any drug that prolongs the QT interval. (2) Given the primary CNS effects of GEODON, caution should be used when it is taken in combination with other centrally acting drugs. (3) Because of its potential for inducing hypotension, GEODON may enhance the effects of certain antihypertensive agents. (4) GEODON may antagonize the effects of levodopa and dopamine agonists. Effect of Other Drugs on GEODON: *Carbamazepine*, 200 mg bid for 21 days, resulted in a decrease of approximately 35% in the AUC of GEODON. *Ketoconazole*, a potent inhibitor of CYP3A4, 400 mg qd for 5 days, increased the AUC and C_{max} of GEODON by about 35%-40%. *Cimetidine*, 800 mg qd for 2 days, did not affect GEODON pharmacokinetics. Coadministration of 30 mL of *Maalox* did not affect GEODON pharmacokinetics. Population pharmacokinetic analysis of schizophrenic patients in controlled clinical trials has not revealed any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam. Effect of GEODON on Other Drugs: In vitro studies revealed little potential for GEODON to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and little potential for drug interactions with GEODON due to displacement. GEODON 40 mg bid administered concomitantly with *lithium* 450 mg bid for 7 days did not affect the steady-state level or renal clearance of lithium. GEODON 20 mg bid did not affect the pharmacokinetics of concomitantly administered *oral contraceptives*, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg). Consistent with in vitro results, a study in normal healthy volunteers showed that GEODON did not alter the metabolism of *dextromethorphan*, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio. ***Carcinogenesis, Mutagenesis, Impairment of Fertility:*** Lifetime carcinogenicity studies were conducted with GEODON in Long Evans rats and CD-1 mice. In male mice, there was no increase in incidence of tumors relative to controls. In female mice there were dose-related increases in the incidences of pituitary gland adenoma and carcinoma, and mammary gland adenocarcinoma at all doses tested. Increases in serum prolactin were observed in a 1-month dietary study in female, but not male, mice. GEODON had no effect on serum prolactin in rats in a 5-week dietary study at the doses that were used in the carcinogenicity study. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see Hyperprolactinemia). Mutagenesis: There was a reproducible mutagenic response in the Ames assay in one strain of *S. typhimurium* in the absence of metabolic activation. Positive results were obtained in both the in vitro mammalian cell gene mutation assay and the in vitro chromosomal aberration assay in human lymphocytes. Impairment of Fertility: GEODON increased time to copulation in Sprague-Dawley rats in two fertility and early embryonic development studies at doses of 10 to 160 mg/kg/day (0.5 to 8 times the MRHD of 200 mg/day on a mg/m^2 basis). Fertility rate was reduced at 160 mg/kg/day (8 times the MRHD on a mg/m^2 basis). There was no effect on fertility at 40 mg/kg/day (2 times the MRHD on a mg/m^2 basis). The fertility of female rats was reduced. ***Pregnancy—Pregnancy Category C:*** There are no adequate and well-controlled studies in pregnant women. GEODON should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. ***Labor and Delivery:*** The effect of GEODON on labor and delivery in humans is unknown. ***Nursing Mothers:*** It is not known whether, and if so in what amount, GEODON or its metabolites are excreted in human milk. It is recommended that women receiving GEODON should not breast feed. ***Pediatric Use:*** The safety and effectiveness of GEODON in pediatric patients have not been established. ***Geriatric Use:*** Of the approximately 4500 patients treated with GEODON in clinical studies, 2.4% (109) were 65 years of age or over. In general, there was no indication of any different tolerability for GEODON or of reduced clearance of GEODON in the elderly compared to younger adults. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to GEODON, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients. **ADVERSE REACTIONS — *Adverse Findings Observed in Short-term, Placebo-Controlled Trials:*** The following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which GEODON was administered in doses ranging from 10 to 200 mg/day. ***Adverse Events Associated with Discontinuation:*** Schizophrenia: Approximately 4.1% (29/702) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 2.2% (6/273) on placebo. The most common event associated with dropout was rash, including 7 dropouts for rash among GEODON patients (1%) compared to no placebo patients (see **PRECAUTIONS**). Bipolar Mania: Approximately 6.5% (18/279) of GEODON-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse event, compared with about 3.7% (5/136) on placebo. The most common events associated with dropout in the GEODON-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash, and vomiting, with 2 dropouts for each of these events among GEODON patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse events. ***Adverse Events at an Incidence ≥5% and at Least Twice the Rate of Placebo:*** The most commonly observed adverse events associated with GEODON in schizophrenia trials were somnolence (14%) and respiratory tract infection (8%). The most commonly observed adverse events associated with the use of GEODON in bipolar mania trials were somnolence (31%), extrapyramidal symptoms (31%), dizziness (16%), akathisia (10%), abnormal vision (6%), asthenia (6%), and vomiting (5%). The following list enumerates the treatment-emergent adverse events that occurred during acute therapy, including only those events that occurred in 2% of GEODON patients and at a greater incidence than in placebo. Schizophrenia: Body as a Whole—asthenia, accidental injury, chest pain. Cardiovascular—tachycardia. Digestive—nausea, constipation, dyspepsia, diarrhea, dry mouth, anorexia. Nervous—extrapyramidal symptoms, somnolence, akathisia, dizziness. Respiratory—respiratory tract infection, rhinitis, cough increased. Skin and Appendages—rash, fungal dermatitis. Special Senses—abnormal vision. Bipolar Mania: Body as a Whole—headache, asthenia, accidental injury. Cardiovascular—hypertension. Digestive—nausea, diarrhea, dry mouth, vomiting, increased salivation, tongue edema, dysphagia. Musculoskeletal—myalgia. Nervous—somnolence, extrapyramidal symptoms, dizziness, akathisia, anxiety, hypesthesia, speech disorder. Respiratory—pharyngitis, dyspnea. Skin and Appendages—fungal dermatitis. Special Senses—abnormal vision. ***Dose Dependency:*** An analysis for dose response in the schizophrenia trials revealed an apparent relation of adverse event to dose for the following: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision. ***Extrapyramidal Symptoms (EPS):*** The incidence of reported EPS for GEODON patients in the short-term, placebo-controlled schizophrenia trials was 14% vs 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale and the Barnes Akathisia Scale did not generally show a difference between GEODON and placebo. ***Dystonia:*** Prolonged abnormal contractions of muscle groups may occur in susceptible individuals during first few days of treatment. Dystonia may occur at any dose level but with greater frequency and severity with high potency and at higher doses of first generation antipsychotic drugs. Elevated risk is observed in males and younger age groups. ***Vital Sign Changes:*** GEODON is associated with orthostatic hypotension (see **PRECAUTIONS**). ***Weight Gain:*** In short-term schizophrenia trials, the proportions of patients meeting a weight gain criterion of ≥7% of body weight were compared, revealing a statistically significantly greater incidence of weight gain for GEODON patients (10%) vs placebo patients (4%). A median weight gain of 0.5 kg was observed in GEODON patients vs 0.0 kg in placebo patients. Weight gain was reported as an adverse event in 0.4% of both GEODON and placebo patients. During long-term therapy with GEODON, a categorization of patients at baseline on the basis of body mass index (BMI) showed the greatest mean weight gain and the highest incidence of clinically significant weight gain (>7% of body weight) in patients with a low BMI (<23) compared to normal (23-27) or overweight (>27) patients. There was a mean weight gain of 1.4 kg for patients with a "low" baseline BMI, 0.0 kg for patients with a "normal" BMI, and a 1.3 kg mean weight loss for patients with a "high" BMI. ***ECG Changes:*** GEODON is associated with an increase in the QT_c interval (see **WARNINGS**). In schizophrenia trials, GEODON was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients. ***Other Adverse Events Observed During the Premarketing Evaluation of GEODON:*** Frequent adverse events are those occurring in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Schizophrenia: Body as a Whole — *Frequent:* abdominal pain, flu syndrome, fever, accidental fall, face edema, chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident. Cardiovascular System — *Frequent:* tachycardia, hypertension, postural hypotension; *Infrequent:* bradycardia, angina pectoris, atrial fibrillation; *Rare:* first-degree AV block, bundle branch block, phlebitis, pulmonary embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis. Digestive System — *Frequent:* anorexia, vomiting; *Infrequent:* rectal hemorrhage, dysphagia, tongue edema; *Rare:* gum hemorrhage, jaundice, fecal impaction, gamma glutamyl transpeptidase increased, hematemesis, cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena. Endocrine — *Rare:* hypothyroidism, hyperthyroidism, hypothyroidism. Hemic and Lymphatic System — *Infrequent:* anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, lymphadenopathy; *Rare:* thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia. Metabolic and Nutritional Disorders — *Infrequent:* thirst, transaminase increased, peripheral edema, hyperglycemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia; *Rare:* BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, glucose tolerance decreased, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypoglycemic reaction, hypomagnesemia, ketosis, respiratory alkalosis. Musculoskeletal System — *Frequent:* myalgia; *Infrequent:* tenosynovitis; *Rare:* myopathy. Nervous System — *Frequent:* agitation, extrapyramidal syndrome, tremor, dystonia, hypertonia, dyskinesia, hostility, twitching, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy; *Infrequent:* paralysis; *Rare:* myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus. Respiratory System — *Frequent:* dyspnea; *Infrequent:* pneumonia, epistaxis; *Rare:* hemoptysis, laryngismus. Skin and Appendages — *Infrequent:* maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash. Special Senses — *Frequent:* fungal dermatitis; *Infrequent:* conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia; *Rare:* eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis. Urogenital System — *Infrequent:* impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention, metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria; *Rare:* gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage. **Adverse Finding Observed in Trials of Intramuscular GEODON:** In these studies, the most commonly observed adverse events associated with the use of intramuscular GEODON (≥5%) and observed at a rate on intramuscular GEODON (in the higher dose groups) at least twice that of the lowest intramuscular GEODON group were headache (13%), nausea (12%), and somnolence (20%). **Adverse Events at an Incidence >1% in Short-Term Fixed-Dose Intramuscular Trials:** The following list enumerates the treatment-emergent adverse events that occurred in ≥1% of GEODON patients (in the higher dose groups) and at least twice that of the lowest intramuscular GEODON group. Body as a Whole—headache, injection site pain, asthenia, abdominal pain, flu syndrome, back pain. Cardiovascular—postural hypotension, hypertension, bradycardia, vasodilation. Digestive—nausea, rectal hemorrhage, diarrhea, vomiting, dyspepsia, anorexia, constipation, tooth disorder, dry mouth. Nervous—dizziness, anxiety, insomnia, somnolence, akathisia, agitation, extrapyramidal syndrome, hypertonia, cogwheel rigidity, paresthesia, personality disorder, psychosis, speech disorder. Respiratory—rhinitis. Skin and Appendages—furunculosis, sweating. Urogenital—dysmenorrhea, priapism. **DRUG ABUSE AND DEPENDENCE — *Controlled Substance Class:*** GEODON is not a controlled substance. **OVERDOSAGE**—In premarketing trials in over 5400 patients, accidental or intentional overdosage of GEODON was documented in 10 patients. All patients survived without sequelae. In the patient taking the largest confirmed amount (3240 mg), the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (BP 200/95).

Revised August 2008

Essential New TEXTBOOKS in PSYCHIATRY



The American Psychiatric Publishing Textbook of Psychiatry

Edited by
Robert E. Hales, M.D., M.B.A.,
Stuart C. Yudofsky, M.D.,
and Glen O. Gabbard, M.D.

With Foreword by
Alan F. Schatzberg, M.D.

This book has been meticulously revised by more than 100 contributors—65 new to this edition—summarize the latest developments in psychiatry, with new chapters on cellular and molecular biology; neuroanatomy; human sexuality and sexual dysfunctions; nonpharmacological somatic treatments; supportive psychotherapy; combined psychotherapy and pharmacotherapy; treatment of gay, lesbian, bisexual, and transgender patients; and assessment of dangerousness.

2008 • 1,818 pages
ISBN 978-1-58562-257-3
Hardcover • $285.00
Item #62257



The American Psychiatric Publishing Textbook of Substance Abuse Treatment, Fourth Edition

Edited by Marc Galanter, M.D., and Herbert D. Kleber, M.D.

This book has been fully updated to present the most current scientific and clinical information on a wide range of substance use disorders. It is a comprehensive guide to treatment written at a level appropriate to both experienced and new clinicians, reflecting the expertise of leading addiction specialists in psychiatry and allied fields. With most chapters extensively revised by new authors, it incorporates the latest biomedical research findings as well as recent advances in treatment modalities and the growth of pharmacotherapies.

2008 • 768 pages
ISBN 978-1-58562-276-4
Hardcover • $165.00
Item #62276



Textbook of Psychotherapeutic Treatments

Edited by Glen O. Gabbard, M.D.

Glen O. Gabbard, author or editor of more than 22 books and over 280 scientific papers and book chapters, is a leader in the fields of psychiatry and psychoanalysis. He has assembled 50 of the world's most renowned experts in every psychotherapeutic school of thought to create this definitive volume, sure to become the standard text for all student and practicing psychotherapists.

Treatment outcome depends on carefully matching the therapeutic modality to the patient or client, and this book will both facilitate and enhance that meticulous process. Up-to-date and scientifically rigorous, this book is the "go-to" reference for the conscientious psychotherapist.

2009 • 944 pages
ISBN 978-1-58562-304-4
Hardcover • $95.00
Item #62304



The American Psychiatric Publishing Textbook of Geriatric Psychiatry, Fourth Edition

Dan G. Blazer, M.D., Ph.D.,
David C. Steffens, M.D., M.H.S.

Widely recognized as the standard in its field, *The American Psychiatric Textbook of Geriatric Psychiatry* has been revised and updated while continuing the tradition of providing both scholar and clinician with the practical skills and knowledge required for understanding mental disorders in later life. It offers an authoritative review of a wide range of topics written by leaders in geriatric psychiatry, gerontology, geriatric medicine, and geriatric nursing, offering a solid grounding in both basic science and clinical applications.

2009 • 720 pages
ISBN 978-1-58562-277-1
Hardcover • Item #62277

Special prepublication price of $134.00 until February 28, 2009 (thereafter $149.00)

American Psychiatric Publishing, Inc.

The *First* and *Last* Word in Psychiatry

Order Online: www.appi.org • Phone: 1-800-368-5777 • Fax: 703-907-1091 • Email: appi@psych.org

Priority Code AH903

PsychiatryOnline.com

Online access to a premier collection of psychiatric resources

Just added to **PsychiatryOnline**



Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems

A Resource Book of Medication Information Handouts, Third Edition

Edited by Mina K. Dulcan, M.D.



PsychiatryOnline.com is a powerful website that features *DSM-IV-TR*® and *The American Journal of Psychiatry* as the cornerstones of an unsurpassed collection of psychiatric references, including books, journals, and self-assessment tools. Much more than simply books and journals presented online, **PsychiatryOnline.com** features sophisticated searching and indexing tools that enable you to quickly target all the information you need.

Whether your needs are clinical, learning, or research, **PsychiatryOnline.com** provides access to the information critical to your work and everyday practice with convenient features such as:

- Search and linking tools that let you find relevant book chapters and journal articles quickly.
- Unlimited downloads to PDA so you can take book sections with you wherever you go.
- Copy and paste functions for easy creation of tables and presentations.
- Citation exports to most reference manager formats.
- Printer-friendly views that mean no reformatting when you need a hard copy.
- Saved searches and bookmarked chapters to make it easy to return to topics of interest.
- Email page feature that allows you to share the information with colleagues.

Other subscriber benefits include:

- Book of the Month—You'll get access each month to a FREE PDF version of a featured book from American Psychiatric Publishing, Inc.
- The most up-to-date versions available including NEW *American Psychiatric Association Practice Guidelines* as they are released.
- PLUS Guideline Watches and DSM-IV-TR Coding Updates, as soon as they are available.
- American Psychiatric Association Members receive $110 discount off a regular priced subscription. APA Members-in-Training (MITs) can save even more!

Subscribe TODAY, visit
www.PsychiatryOnline.com.

Please enter priority code AH904AA when completing your request.

Interested in an institutional subscription? Please contact us at institutions@psych.org or call 1-800-368-5777 ext. 8538 or 703-907-8538 more information and a subscription rate quote.

American Psychiatric Publishing, Inc.

The *First* and *Last* Word in Psychiatry

AH904

Putting people's lives together… and improving yours.

There are great challenges awaiting today's Psychiatrists in correctional mental health. The diversity of diagnoses is enormous. Just think of the impact you could have on individual lives while enjoying:

- **Less red tape and no managed care restrictions**
- **No reimbursement hassles**
- **A schedule conducive to better work/life balance**
- **28 paid days off per year plus 6 company-paid holidays**
- **CEU reimbursement with 4 additional paid days off**
- **Paid malpractice coverage**
- **Excellent, guaranteed salaries**
- **401(k) plan with employer match**
- **Company-sponsored health, life and disability insurance**

Of course, safety is a number one priority at all of our locations.

265 facilities in 13 states nationwide with openings currently in:

Central Georgia
Michigan - Statewide
Western Tennessee
Montgomery, Alabama
Pennsylvania - Statewide
Waterbury, Vermont

Contact **Vikkie Schill at (877) 282-5811 or vikkie@mhmcareers.com.**

www.mhm-services.com
EOE

MHM Services, Inc.

ADULT PSYCHIATRIST

Adult Psychiatrists, Board Eligible or Certified, for 20 to 40 hr. outpatient psychiatry positions to work at **North Suffolk Mental Health** Association.

Candidate/s will be lead psychiatrist for a Multidisciplinary Team at one or more Community Counseling Centers located in Chelsea, East Boston, and/or Revere.

Job entails psychiatric evaluations and medication follow-up appointments, as well as being lead psychiatrist providing consultation to weekly multidisciplinary team meetings. Additional duties may include consultation to a number of Community Based Programs and may have the opportunity to supervise a prescribing CNP, clinical staff, and may supervise MGH/McLean Residents. An MGH/Harvard appointment is possible with the right credentials.

Bilingual/Bicultural/Cultural Competence in Spanish highly preferred. Background in Substance Treatment a plus. Excellent Pay based on background and experience; generous benefit package.

Please submit CV to Maura Cox, Recruiter at: **gethired@northsuffolk.org or contact Nancy McDonnell, MD at nmcdonnell@northsuffolk.org. EOE**

NORTH SUFFOLK Mental Health Association

EOE

Psychiatry Opportunities

VA Central California Health Care System is recruiting for three (3) full- time academically oriented psychiatrists to work in our, Buprenorphine Treatment Program, 12-bed Inpatient Unit, or Outpatient Mental Health Clinic PTSD Program. The VA is a core training site for the UCSF-Fresno Residency Training Program in several specialties to include psychiatry, and others. With a faculty appointment, opportunities for resident supervision, teaching and clinical research will be available. Board Certification is required. Qualification of psychiatrist should be at minimum: licensed in the State of California, Board Certified in the practice of adult psychiatry, and be a citizen of the United States, or permanent resident alien.

Salary range is $150,000 - $175,000 with potential for a recruitment bonus. Eligibility for Education Debt Reduction Program, if funds are available. Fresno is located in the beautiful San Joaquin Valley, 3 hours from San Francisco, and 4 hours from Los Angeles and 2 hours from three national parks, including Yosemite, and year-round recreation.

Interested applicants should submit their CV and three references to:

Eva Gosselin, HR Specialist, (559) 241-6454, VACCHCS (050)
2615 E. Clinton Ave, Fresno, CA 93703 or
e-mail at eva.gosselin@va.gov . EOE.

#1 Integrated Health System
- ✓ Top 10 Clinic!
- ✓ Top 10 Hospital
- ✓ Low Cost Living

- Flexible Scheduling
- Family Friendly practice and community of 200K
- 30 Bed Inpatient Unit

A Psychiatrist, BC / BE, is being sought to join a three-physician Adult practice. Enjoy your life and practice with long-term physicians and staff. St. John's Clinic is a 480 physician multi-specialty clinic offering a very large referral base!

St. John's Regional Health Center, Springfield, Missouri is an 886-bed, level-one trauma center. St. John's Hospital serves as a referral hospital for 6+ regional hospitals serving 40 communities and covering 25,000 square miles.

SPRINGFIELD, MISSOURI, is located three hours south and southwest of Kansas City and St. Louis, respectively. A growing mid-sized city in the foothills of the Ozark Mountains, Springfield offers everything from Broadway performances and minor league and Division I athletics to outstanding schools and some of the best outdoor sporting opportunities available. Employment Review named Springfield one of the 20 "Best Places to Live and Work" in the U.S. Housing costs, projected job growth, education, healthcare, taxes, recreation, the arts, and general cost of living rates, make living and working here a pleasure. For more information about Springfield, go to www.springfieldmo.org.

For more information, please contact:
Julie A. Oliver,
Physician Recruiter
St. John's Clinic
Phone: 800-218-5079
Fax: 888-290-8300
E-mail: JAOliver@mercy.net
EOE/AA Employer

MERCY ST. JOHN'S

ST. JOHN'S Clinic

Psychiatrists - Wisconsin

Marshfield Clinic is nationally recognized for providing physicians with the most advanced medical equipment and health information technology today.

We have openings for BE/BC Adult Psychiatrists to join our expanding services. At our Marshfield campus, candidates with fellowship training in neuropsychiatry, geriatric psychiatry or consultative psychiatry are preferred. **Additional practice opportunities are also available at our various clinics throughout Wisconsin.** These primarily outpatient practices can be a mix of C/A and adult patients and employ a multidisciplinary team approach.

With over 770 physicians practicing at 43 locations throughout Wisconsin, Marshfield Clinic is the leader in providing high quality health care to the region. We have created an atmosphere for a clinical practice that exceeds most others. We offer physicians an excellent practice in an academic setting with opportunities for research and teaching. In addition, you will be in the midst of excellent school systems, and safe, friendly communities with easy access/proximity to major metropolitan areas including Chicago and Minneapolis.

To learn more about these opportunities and the very competitive compensation package, please contact: Beth Albee, Physician Recruitment, Marshfield Clinic, 1000 N. Oak Ave., Marshfield, WI 54449. **Phone:** 800-782-8581, extension 19775; **Fax #:** 715-221-9779. **E-mail:** albee.beth@marshfieldclinic.org **Website:** www.marshfieldclinic.org/recruit

MARSHFIELD CLINIC®

Where the future of medicine lives

Marshfield Clinic is an Affirmative Action/Equal Opportunity employer that values diversity. Minorities, females, individuals with disabilities and veterans are encouraged to apply. Sorry, not a health professional shortage area.

Assistant/Associate Professor
(Director; Inpatient Academic Teaching Unit)

The Department of Psychiatry at the **University of Illinois (Chicago Campus)** is seeking an innovative clinician-educator (tenured or non-tenured) with experience and interest in clinical research to lead a 36 bed adult inpatient unit. This unit has specialty services in women's mental health, psychotic disorders, mood and anxiety disorders, neuropsychiatry and some active clinical research. Interest in clinical research is highly desirable. In addition to work on the inpatient service, a limited amount of clinical work in the ambulatory setting is expected.

This is a full time position on our clinician-educator track. The successful candidate will have had a minimum of three to five years experience providing clinical inpatient care, supervising other attending physicians and staff, building therapeutic milieus and working in a multidisciplinary setting. Experience in clinical administrative activities on an inpatient service or in another clinical milieu is desirable. Interest in teaching and supervising medical students and residents is essential.

Candidates should be Board Certified or Board Eligible in Psychiatry. The successful candidate will be appointed as a faculty member of the Dept of Psychiatry, College of Medicine, rank and salary commensurate with qualifications and experience. Please submit your CV and all contact information along with four letters of recommendation by **12/15/08** to:

Ena Casas
Department of Psychiatry
University of Illinois
1601 W. Taylor Street
Chicago, Illinois 60612
E-mail: ecasas@psych.uic.edu

UIC is an Affirmative Action/Equal Opportunity Employer.
Applications from women and minorities are encouraged.

Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse

National Institute on Drug Abuse • Department of Health and Human Services • National Institutes of Health

The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) is seeking a senior-level scientist with expertise in medications development and the conduct of clinical trials who will bring significant experience to operate in an intellectually challenging Federal biomedical research institution engaged in a national research program to understand the biomedical and social causes and consequences of drug addiction throughout the world.

This is a scientific executive position that offers a unique and challenging opportunity for the right individual to direct an extramural scientific program of national and international scope within NIDA.

The position entails providing leadership in the development of new medications for the treatment of addictive disorders. To accomplish this mission, the division (1) plans and directs studies to identify, evaluate, and develop new medications for Food and Drug Administration (FDA) review and approval; (2) develops and administers a national program of basic and clinical pharmaceutical research, conducted at academic settings, to develop innovative immunological and pharmacological treatment approaches; (3) supports training in the preclinical and clinical sciences; (4) collaborates with the pharmaceutical industry and other Federal medications development programs (e.g., National Institute on Alcohol Abuse and Alcoholism) to facilitate medications development for addictive disorders; and (5) works closely with the FDA to assure that the research designs to show efficacy are evaluated and approved in the most expeditious manner.

The successful candidate will possess an M.D. and/or Ph.D. degree, have knowledge of neuropharmacology and clinical research, and have experience in medications development. The candidate should also possess knowledge on addiction medicine and the neuroscience of addiction. Managerial experience in medications development in the biotechnology or pharmaceutical sectors, or Federal service for at least 5 years is highly desirable. The individual must also have demonstrated ability to manage personnel, budgets, and timelines across multiple fiscal years.

Application Process: Salary is commensurate with experience; a full package of Federal Government benefits is available, including retirement, health and life insurance, long-term care insurance, leave, and retirement savings plan (401K equivalent). Send your application package, including: CV, bibliography, and two letters of recommendation to the National Institutes of Health, Attn: Stephanie Jones, Office of Human Resources; 2115 East Jefferson St., Room 2D-204, Rockville, Maryland 20853, or e-mail jones17@mail.nih.gov; phone: 919-541-7913. For further information on the position, please contact the search committee chair: Barry Hoffer, M.D., by e-mail: bhoffer@intra.nida.nih.gov, or phone: 443-740-2463. Your application package must be received by March 15, 2009. All information provided by applicants will remain confidential and will not be released outside the NIDA search process without a signed release from candidates.

NIH encourages the application and nomination of qualified women, minorities, and individuals with disabilities.
HHS and NIH are Equal Opportunity Employers.

drugabuse.gov

U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
NIDA NATIONAL INSTITUTE ON DRUG ABUSE

RESIDENCY TRAINING DIRECTOR

The Department of Psychiatry at **The University of Texas Health Science Center at San Antonio (UTHSCSA)** seeks a Director of Adult Residency Training. The position is for a full-time board-certified academic psychiatrist at the Associate Professor or Professor level in the tenure or nontenure track.

The ideal candidate will have an emerging or established national reputation, show evidence of leadership and innovation in psychiatric residency training, have outstanding interpersonal skills, and sufficient administrative experience to manage and lead a large residency program.

The fully accredited program includes over 60 residents as well as ACGME approved fellowships in Geriatric and Forensic Psychiatry. Approval is being sought for a Psychosomatic Medicine Fellowship. This unique program includes residency slots from Wilford Hall Air Force Medical Center, University Hospital Health System, and the Audie Murphy Veterans Hospital.

Psychiatry has strong educational, research and clinical programs in an attractive, culturally rich city situated on the edge of the Texas Hill Country, with a pleasant climate, an excellent public school system and abundant recreational activities. Interested individuals should forward their curriculum vitae to:

Pedro L. Delgado, M.D.
Professor and Chairman, Department of Psychiatry
Mail Code 7792
The University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio TX 78229-3900
Phone: 210-567-5391
Fax: 210-567-6941

The University of Texas Health Science Center at San Antonio is an Equal Employment Opportunity/Affirmative Action Employer. All faculty appointments are designated as security sensitive positions.

PSYCHIATRISTS

The VA Needs You

Shreveport, LA	Pensacola, FL	Fayetteville, AR
Alexandria, LA	Mt. Vernon, MO	Fort Smith, AR
Biloxi, MS	Muskogee, OK	Mobile, AL

Psychiatrist positions require: BE/BC Psychiatrists, current, full, unrestricted licensure (any state), U.S. citizen Great Benefits, Excellent Pay, Rewarding Work. See announcements on www.vacareers.va.gov. Recruitment/Relocation incentives may be authorized, ask contact individual for details.

BILOXI/PENSACOLA Outpatient and Inpatient Psychiatry positions. Expertise in substance abuse, geropsychiatry and PTSD preferred. BE/BC psychiatrist, state license (any state), U.S. citizen or permanent resident. Send applications to Jean Williams, HRMS (05A), 400 Veterans Avenue, Biloxi, MS or contact at jean.williams@med.va.gov or (228) 523-5633.

ALEXANDRIA Strong Clinical Skills. Prefer experience in General Outpatient, Inpatient Psychiatry, and Substance Abuse. CV/Application to heather.ball@va.gov or mail to Heather Ball/Psychiatry Service (116), P.O. Box 69004, Alexandria, LA 71306-9004. For additional questions, please call (318) 466-2958.

SHREVEPORT Prefer experience in Substance Abuse, PTSD. Contact Kathy Arroyo at (318)990-5154 or email at Kathy.arroyo@va.gov. Email or mail your CV to VAMC, HRMS (05) KA, 510 E. Stoner Ae, Shreveport, LA 71101.

FAYETTEVILLE, FORT SMITH, ARKANSAS; BRANSON, MISSOURI Contact Betty Gray (479)443-4301 ext 5188 or email: betty.gray@va.gov.

MUSKOGEE, OK Contact Jason Cleveland, HRMS at 918-577-3800.

JACKSON, MISSISSIPPI Prefer experience in general psychiatry, including inpatient, outpatient, consultative, or telemedicine psychiatry. Interested candidates should submit a CV to Felicia Owens, Human Resources (05P), VA Medical Center, 1500 E. Woodrow Wilson Dr., Jackson, MS 39216 or Felicia.ovens@va.gov phone: 601-364-1575.

University of Pittsburgh

School of Medicine
Chair, Department of Psychiatry
Western Psychiatric Institute and Clinic

The University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center (UPMC) are seeking applications and nominations for the position of professor and chair of the Department of Psychiatry and medical director of Western Psychiatric Institute and Clinic (WPIC) of UPMC. The department is dedicated to providing high-quality mental health care while developing and maintaining innovative basic and clinical research programs aimed at advancing clinical practice. The department is the nation's leading recipient of National Institutes of Health (NIH) research funding in the field and home to world-class education and training programs. The department's research program embraces a collaborative format, forming translational bridges focused on the etiology of mental disorders, clinical treatment trials, methodological concerns, behavioral medicine, and outcome evaluation.

Competitive candidates must be board-certified psychiatrists whose academic accomplishments meet criteria for appointment at the tenured professor level, including a distinguished record of research, teaching, publication, and service. Other key characteristics include a broad visionary approach to major issues in contemporary psychiatry, the ability to foster extensive collaborations, significant administrative experience, and evidence of strong leadership skills.

The University of Pittsburgh School of Medicine is one of the nation's leading medical schools, renowned for its curriculum that emphasizes both the science and humanity of medicine and its remarkable growth in NIH grant support, which has more than doubled since 1998. For fiscal year 2007, the University ranked sixth out of more than 3,000 entities receiving NIH support. As one of the University's six Schools of the Health Sciences, the School of Medicine is the academic partner to UPMC. Their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease, and participate in the delivery of outstanding patient care.

Review of applications will begin immediately and continue until the position is filled. Candidates should submit a letter of application stating professional accomplishments; curriculum vitae; and the names, mailing addresses, e-mail addresses, and telephone numbers of five professional references. Electronic applications and nominations are preferred and should be sent to mmaggie@pitt.edu, with "Psychiatry Chair Search" entered into the e-mail subject line. Applications and nominations may also be submitted by mail and should be sent to:

Steven Shapiro, MD
Chair, Psychiatry Chair Search Committee
University of Pittsburgh School of Medicine
Suite 401 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
USA

University of Pittsburgh

The University of Pittsburgh is an affirmative action,equal opportunity employer. Women and minority candidates are strongly encouraged to apply.

UTMB Correctional Managed Care

WANTED: HIGH QUALITY PSYCHIATRISTS

UTMB-CMC employs Psychiatrists at multiple adult and juvenile facilities all over Texas. We currently have multiple locations for child/adolescent experienced psychiatrists. We are heavy utilizers of telepsychiatry using state of the art technology and an electronic medical records.

We are a correctional healthcare system that is setting the standard for others. Correctional Managed Care is among the world's leaders in telemedicine and electronic medical record applications. Innovative programs, creative solutions and participation in the Baldridge National Quality Program further define our organization and help lead us toward performance excellence.

Current Opportunities Available

- ✓ BROWNWOOD: Staff Psychiatrist – Youth Services
- ✓ MART: Staff Psychiatrist – Youth Servicesl
- ✓ AUSTIN: Staff Psychiatrist – Telemedicine Center
- ✓ CORSICANA: Staff Psychiatrist – Youth Services
- ✓ Positions also available for Psychiatric Physician Assistants and Nurse Practitioners

Compare our benefits with other organizations:

- ✓ Relocation allowance
- ✓ $2000 CME stipend per fiscal year
- ✓ 5 days paid CME leave
- ✓ Competitive salaries
- ✓ Biannual CMC conferences
- ✓ M-F work schedule-day shift
- ✓ Flexible schedules
- ✓ Limited on-call rotation
- ✓ Professional liability coverage
- ✓ Comprehensive medical coverage
- ✓ Paid vacation, holidays and sick leave
- ✓ State retirement plan in ORP or TRS with State contributions.

Correctional practice eliminates many of the "headaches" of community practice such as dealing with insurance companies including Medicare and Medicaid and malpractice insurance problems.

To learn more about our programs go to:
www.utmb.edu/cmc
To Apply contact Debie Dansbe 409-747-2619 or 866-900-2622
or email resume: dsdansbe@utmb.edu

UTMB is an EO/AA Employer M/F/D/V

PARTNER WITH A MAGNET HOSPITAL

BC/BE Psychiatrist needed to serve as Medical Director of an 11-bed Inpatient Behavioral Health Services Unit and to add capacity for our Outpatient Program.

Call is shared with 5 local psychiatrists. Practice is located at Aspirus Wausau Hospital, named in the top 100 hospitals in the USA by *US News and World Report*. Work with a great team of young, vibrant psychiatrists. There is great potential for program growth and development with a focus on expanded community action. Excellent compensation and benefit package included.

As you work within the open and inviting architecture of Aspirus, you will be part of our outstanding award-winning facility. We invite you to join a first-rate medical community and a family-friendly quality of life in north central Wisconsin.

Please contact Jamie Sitko today at 800-792-8728
or fax CV to 715-847-2742.
Email: jamiesi@aspirus.org
www.aspirus.org

ASPIRUS
Passion for excellence. Compassion for people.

UNIVERSITY of TORONTO

The Department of Psychiatry at the **University of Toronto** is conducting a search for the **joint position of Tapscott Chair in Schizophrenia Studies and Head of the Schizophrenia Program**. The position is situated at the **Centre for Addiction and Mental Health (CAMH)**.The Department of Psychiatry at the **University of Toronto** has one of the largest concentrations of faculty and students in the mental health field in the world.

Academic activities are organized into 14 priority programs including schizophrenia **(www.utpsychiatry.ca)**. The **Centre for Addiction and Mental Health** is Canada's leading addictions and mental health facility, fully affiliated with the Department of Psychiatry and designated as a centre of excellence by the World Health Organization **(www.camh.net)**. It enjoys a high profile international reputation and plays a key role in influencing health policy at all levels of government.

The successful candidate will be a productive clinician-scientist. He/she will be responsible for developing a strong interdisciplinary university program in schizophrenia research (basic, clinical and population) and education with a centre of excellence at **CAMH**. Overall success will be measured by the evolution of a stimulating academic program, characterized by recruitment and retention of productive faculty members, external funding and peer-reviewed publications and the active participation of students and fellows.

The successful candidate will be a senior clinician-scientist with a strong record of independent scholarship in the schizophrenia field and with evidence of success in providing leadership and educating and mentoring students and junior faculty members. He/she will be eligible for an academic appointment at the Professor or Associate Professor level.

Please reply with a letter of interest and current curriculum vitae to:

Dr. Donald A. Wasylenki, Professor and Chair
Department of Psychiatry, University of Toronto
CAMH-College Site/250 College Street Suite 835
Toronto, ON CANADA M5T 1R8

The deadline for submissions is February 28, 2009

The University of Toronto is strongly committed to diversity within its community. The University especially welcomes applications from visible minority group members, women, aboriginal persons, persons with disabilities, members of sexual minority groups and others who may contribute to the further diversification of ideas. All qualified candidates are encouraged to apply; however Canadians and permanent residents of Canada will be given priority.

Index to Advertisers
January 2009

The publication of an advertisement in this journal does not imply endorsement of the product or service by the American Psychiatric Association.

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901. Subscriptions (per year): individual $205.00, international $308.00. For additional subscription options, including single issues and student rates, please contact Customer Service at 1-800-368-5777 or email appi@psych.org. Institutional subscriptions are tier priced. For institutional site license or pricing information, contact Customer Service or visit http://highwire.stanford.edu/tfocis/.

Business communications, address changes, and subscription questions from APA members should be directed to the Division of Member Services: (888) 35-PSYCH (toll-free). Nonmember subscribers should call the Circulation Department (800) 368-5777. Author inquiries should be directed to the Journal editorial office: (703) 907-7885 or (703) 907-7884; fax (703) 907-1096; e-mail ajp@psych.org.

Business Management: Nancy Frey, Director, Publishing Services; Laura G. Abedi, Associate Director, Production; Brian Skepton, Advertising Sales and Marketing Manager, Nonpharmaceutical and Online Sales; Alison Jones, Advertising Prepress Manager; Robert Pursell, Director, Sales and Marketing.

Advertising Information: (703) 907-8553; American Psychiatric Publishing, Inc., 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901

Pages are produced using Adobe FrameMaker+ SGML 6.0. Printed by RR Donnelley, Mendota, IL., on acid-free paper effective with Volume 164, Number 11, November 2007.

Periodicals postage paid at Arlington, VA, and additional mailing offices. POSTMASTER: Send address changes to The American Journal of Psychiatry, Circulation Department, American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

Employers and Candidates Connect through the APA Job Bank

Employers

- Post your psychiatric position with the APA Job Bank at **psych.org/jobbank** and reach qualified professionals.
- Use the many resources of the APA Job Bank to make a smart recruitment decision.
- Advertise in the *Psychiatric Services* or *Psychiatric News* classifieds and the APA Job Bank and receive a 10% discount on each.
- Post your psychiatric position with the APA Job Bank before the APA Annual Meeting in San Francisco, May 16-21, and use the Conference Connection to set up interviews with candidates at the meeting.

Candidates

- Search the most comprehensive online listing of psychiatric positions at **psych.org/jobbank**.
- Register to post your resume, receive instant job alerts, use the career tools and more.
- Visit the APA Job Bank and find the ideal position.
- Use the APA Job Bank's Conference Connection to contact prospective employers and set up interviews at the APA Annual Meeting in San Francisco, May 16-21.

To post your psychiatric position, contact:

Pamela Trujillo
Advertising Sales Specialist
P: 703-907-7330
F: 703-907-1093
E: ptrujillo@psych.org

“EACH DAY IS CHALLENGING. EACH DAY IS DIFFERENT. EACH DAY IS REWARDING...”

Lieutenant Wendy Pettit, Behavioral Health Social Worker
U.S. Public Health Service Commissioned Corps

BE A LEADER IN MENTAL HEALTH.

Mental health officers in the U.S. Public Health Service Commissioned Corps are part of an elite team bringing mental and behavioral health services to people most in need. Under a new partnership with the U.S. Department of Defense, Commissioned Corps officers may be detailed to military medical treatment facilities. These officers will provide psychiatric services, counseling, and family and group therapy to returning war fighters, their family members, and military retirees. Corps officers are rewarded with an excellent package of salary and benefits, including health coverage, tax-free allowances for housing and food, 30 days of vacation each year, and much more.

AMERICA'S HEALTH RESPONDERS
COMMISSIONED CORPS
U.S. PUBLIC HEALTH SERVICE

READY TO MAKE A DIFFERENCE?

MAKE THE U.S. PUBLIC HEALTH SERVICE COMMISSIONED CORPS THE HIGHLIGHT OF YOUR CAREER.

The U.S. Department of Health and Human Services is an equal opportunity employer.

www.usphs.gov **1–800–279–1605**

DEPARTMENT OF HEALTH AND HUMAN SERVICES • USA
US PUBLIC HEALTH SERVICE • 1798